Bicara Therapeutics's three largest insider shareholders as of March 23, 2026 are Capital Management, L.P. Ra (Director, 4.60Mn shares), Llc Fmr (Other, 1.12Mn shares), Ltd Biocon (TenPercentOwner, 1.08Mn shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Capital Management, L.P. Ra | 0 | 4,603,418 | 02 Mar, 2026 | |
| Llc Fmr | 0 | 1,115,333 | 18 Sep, 2024 | |
| Ltd Biocon | 0 | 1,080,775 | 16 Sep, 2024 | |
| Ltd Fil | 0 | 1,013,853 | 18 Sep, 2024 | |
| James E Flynn | 0 | 897,587 | 17 Sep, 2024 | |
| Kiran Mazumdar-Shaw | 0 | 432,736 | 16 Sep, 2024 | |
| Claire Mazumdar | Chief Executive Officer | 339,392 | 0 | 20 Mar, 2026 |
| Ryan Cohlhepp | President And Coo | 200,641 | 0 | 17 Mar, 2026 |
| Ivan Hyep | Chief Financial Officer | 145,355 | 0 | 05 Mar, 2026 |
| David Raben | Chief Medical Officer | 55,286 | 0 | 05 Mar, 2026 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 18 Mar, 2026 | Claire Mazumdar | Common Stock | A | 6,499 | $3.79 | 345,891 | D | M |
| 18 Mar, 2026 | Claire Mazumdar | Common Stock | D | 6,499 | $18.84 | 339,392 | D | S |
| 19 Mar, 2026 | Claire Mazumdar | Common Stock | A | 6,905 | $3.79 | 346,297 | D | M |
| 19 Mar, 2026 | Claire Mazumdar | Common Stock | D | 6,905 | $18.78 | 339,392 | D | S |
| 20 Mar, 2026 | Claire Mazumdar | Common Stock | A | 1,596 | $3.79 | 340,988 | D | M |
| 20 Mar, 2026 | Claire Mazumdar | Common Stock | D | 1,596 | $18.95 | 339,392 | D | S |
| 18 Mar, 2026 | Claire Mazumdar | Stock Option (Right to Buy) | D | 6,499 | $0.00 | 184,608 | D | M |
| 19 Mar, 2026 | Claire Mazumdar | Stock Option (Right to Buy) | D | 6,905 | $0.00 | 177,703 | D | M |
| 20 Mar, 2026 | Claire Mazumdar | Stock Option (Right to Buy) | D | 1,596 | $0.00 | 176,107 | D | M |
| 16 Mar, 2026 | Ryan Cohlhepp | Common Stock | A | 8,000 | $3.79 | 213,141 | D | M |
| 16 Mar, 2026 | Ryan Cohlhepp | Common Stock | D | 8,000 | $19.66 | 205,141 | D | S |
| 16 Mar, 2026 | Ryan Cohlhepp | Common Stock | D | 4,500 | $19.66 | 200,641 | D | S |
| 16 Mar, 2026 | Ryan Cohlhepp | Stock Option (Right to Buy) | D | 8,000 | $0.00 | 117,334 | D | M |
| 09 Mar, 2026 | Claire Mazumdar | Common Stock | A | 36,766 | $3.79 | 376,158 | D | M |
| 09 Mar, 2026 | Claire Mazumdar | Common Stock | D | 36,766 | $19.17 | 339,392 | D | S |
| 09 Mar, 2026 | Claire Mazumdar | Stock Option (Right to Buy) | D | 36,766 | $0.00 | 191,107 | D | M |
| 04 Mar, 2026 | Claire Mazumdar | Common Stock | A | 2,631 | $3.79 | 342,023 | D | M |
| 04 Mar, 2026 | Claire Mazumdar | Common Stock | D | 2,631 | $18.73 | 339,392 | D | S |
| 05 Mar, 2026 | Claire Mazumdar | Common Stock | A | 1,786 | $3.79 | 341,178 | D | M |
| 05 Mar, 2026 | Claire Mazumdar | Common Stock | D | 1,786 | $18.74 | 339,392 | D | S |